1. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95
2. Colburn WA (2000) Optimizing the use of biomarkers, surrogate endpoints and clinical endpoints for more efficient drug development. J Clin Pharmacol 40:1419–1427
3. Derendorf H, Lesko L, Chaikin P, Colburn W, Lee P, Miller R, Powell R, Rhodes G, Stanski D, Venitz J (2000) Pharmacokinetic-pharmacodynamic modeling in drug research and development. J Clin Pharmacol 40:1–19
4. Down G (ed) Biomarkers and surrogate endpoints, 1st edn. Elsevier Sciences, Amsterdam, pp 1–9
5. Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW, Peck CC (2001) Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther 69:387–399